Navidea Biopharmaceutical... (NAVB)
Navidea Biopharmaceuticals Statistics
Share Statistics
Navidea Biopharmaceuticals has 100.08M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 100.08M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 64.84M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2.69M, so 2.68% of the outstanding shares have been sold short.
| Short Interest | 2.69M |
| Short % of Shares Out | 2.68% |
| Short % of Float | 4.14% |
| Short Ratio (days to cover) | 0.52 |
Valuation Ratios
The PE ratio is -0.41 and the forward PE ratio is null. Navidea Biopharmaceuticals's PEG ratio is -0.01.
| PE Ratio | -0.41 |
| Forward PE | n/a |
| PS Ratio | 93.86 |
| Forward PS | null |
| PB Ratio | -0.73 |
| P/FCF Ratio | -0.66 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Navidea Biopharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of -0.29.
| Current Ratio | 0.32 |
| Quick Ratio | 0.28 |
| Debt / Equity | -0.29 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.26 |
| Interest Coverage | -12.79 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $5.97K |
| Profits Per Employee | $-1.38M |
| Employee Count | 11 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.43 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.9, so Navidea Biopharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.9 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0 |
| Relative Strength Index (RSI) | 55.96 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Navidea Biopharmaceuticals had revenue of 65.65K and earned -15.18M in profits. Earnings per share was -0.59.
| Revenue | 65.65K |
| Gross Profit | -119.3K |
| Operating Income | -14.05M |
| Net Income | -15.18M |
| EBITDA | -13.88M |
| EBIT | -14.08M |
| Earnings Per Share (EPS) | -0.59 |
Balance Sheet
The company has 2M in cash and 2.44M in debt, giving a net cash position of -439.76K.
| Cash & Cash Equivalents | 2M |
| Total Debt | 2.44M |
| Net Cash | -439.76K |
| Retained Earnings | -388M |
| Total Assets | 5.7M |
| Working Capital | -3.48M |
Cash Flow
In the last 12 months, operating cash flow was -8.99M and capital expenditures -390.35K, giving a free cash flow of -9.38M.
| Operating Cash Flow | -8.99M |
| Capital Expenditures | -390.35K |
| Free Cash Flow | -9.38M |
| FCF Per Share | -0.32 |
Margins
Gross margin is -181.71%, with operating and profit margins of -21402.08% and -23117.58%.
| Gross Margin | -181.71% |
| Operating Margin | -21402.08% |
| Pretax Margin | -23117.58% |
| Profit Margin | -23117.58% |
| EBITDA Margin | -21134.32% |
| EBIT Margin | -21402.08% |
| FCF Margin | -14282.76% |
Dividends & Yields
NAVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for NAVB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 26, 2019. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 26, 2019 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -100.75 |
| Piotroski F-Score | 2 |